Of note, while programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors are superior to chemotherapy in terms of their clinical effectiveness for advanced melanoma patients, combination therapy with anti-PD-1 and anti-CTLA4 antibodies can cause severe immune-related adverse events, which are sometimes life-threatening [1]. This evidence concerns the gene CTLA4 and melanoma.